UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000002456 |
|---|---|
| Receipt number | R000003008 |
| Scientific Title | Phase II study of lapatinib plus capecitabin for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents. |
| Date of disclosure of the study information | 2009/09/07 |
| Last modified on | 2017/11/30 18:04:58 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2009/09/06 16:52:12 | ||
| 2 | Update | 2010/09/06 12:31:50 | Recruitment status |
|
| 3 | Update | 2011/09/06 22:17:14 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 4 | Update | 2011/09/06 22:21:16 | Last follow-up date |
|
| 5 | Update | 2014/03/06 10:41:49 | Last name of lead principal investigator Last name of lead principal investigator |
|
| 6 | Update | 2015/02/16 19:10:38 | Recruitment status Last follow-up date |
|
| 7 | Update | 2017/11/30 18:04:58 | UMIN ID1 |
